# Bayer

Type: Company (BAYRY)

Source: GetYourBrief — https://getyourbrief.com/entity/bayer
Canonical HTML page: https://getyourbrief.com/entity/bayer

## Timeline

- **2047-02-18**: End of Certainty Period — The 21-year structured resolution period is slated to conclude.
- **2026-03-25**: Phase III Initiation — First patient dosed in the pivotal Phase III clinical trial for endometriosis.
- **2026-02-18**: $7.25B Settlement Announced — Bayer agrees to a new $7.25 billion deal with a 21-year certainty plan.
- **2026-02-18**: Future Claims Deal — Bayer reaches a $7.25 billion agreement to resolve future litigation over a 21-year period.
- **2023-06-15**: Phase II Completion — Positive results from Phase II studies demonstrate pain reduction and safety.
- **2020-06-24**: Initial $10B Settlement — Bayer announces a massive settlement to resolve current claims, but future liability remains.
- **2020-06-24**: Initial Settlement — Bayer announces a $10.9 billion settlement to resolve the majority of existing Roundup claims.
- **2019-04-01**: Licensing Agreement — Hope Medicine acquires global rights for HMI-115 from Bayer.
- **2018-08-10**: First Major Verdict — A California jury awards $289M to a groundskeeper, sparking a wave of litigation.
- **2018-06-07**: Monsanto Acquisition — Bayer completes $63 billion acquisition of Monsanto, inheriting Roundup litigation.
- **2018-06-07**: Monsanto Acquisition — Bayer completes the $63 billion acquisition of Monsanto, inheriting Roundup liabilities.

## Recent coverage (5 stories, network-wide)

### Alport Syndrome Market to Hit 47% CAGR Through 2036 on Gene Therapy Pipeline
2026-07-27 09:04:39 · Sector: bio · Sentiment: Strongly positive · Impact: 7/10 · Sources: 2

A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Full story: https://getbiobrief.com/story/alport-syndrome-market-47-cagr-2036-bio

### Hope Medicine Doses First Patient in Phase III Endometriosis Trial for HMI-115
2026-03-25 02:01:10 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Full story: https://getbiobrief.com/story/hope-medicine-phase-3-endometriosis-trial-hmi-115

### Hope Medicine Doses First Phase III Patient in Landmark Endometriosis Trial
2026-03-25 02:00:37 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.
Full story: https://gethealthbrief.com/story/hope-medicine-phase-iii-endometriosis-trial-commences

### Bayer Secures $7.25B Roundup Settlement to End Decades of Legal Uncertainty
2026-02-18 22:26:22 · Sector: finance · Sentiment: Negative · Impact: 8/10 · Sources: 2

Bayer has reached a definitive $7.25 billion settlement to resolve future Roundup litigation, implementing a 21-year framework designed to provide financial and legal certainty. The deal aims to move the German conglomerate past the glyphosate-related liabilities that have weighed on its valuation since the 2018 Monsanto acquisition.
Full story: https://getfinancebrief.com/story/bayer-roundup-settlement-7-billion-21-year-plan

### Bayer Agrees to Landmark $7.25B Roundup Settlement to End Decades of Litigation
2026-02-18 22:25:49 · Sector: bio · Sentiment: Negative · Impact: 8/10 · Sources: 2

Bayer has reached a $7.25 billion settlement agreement to resolve long-standing litigation surrounding its Roundup herbicide. The deal includes a 21-year framework designed to provide legal and financial certainty for the company following years of costly courtroom battles.
Full story: https://getbiobrief.com/story/bayer-7-25b-roundup-settlement-21-year-plan

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.